[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350808-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350808-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","health-related-quality-of-life-in-patients-with-cervical-cancer-a-systematic-review-and-meta-analysis-of-eq-5d-utility-scores","Health-related quality of life in patients with cervical cancer - a systematic review and meta-analysis of EQ-5D utility scores","","Cervical cancer substantially impairs health-related quality of life (HRQoL), creating a need for pooled preference-based evidence for economic evaluation and health technology assessment. This PRISMA 2020-compliant systematic review and meta-analysis searched PubMed, Embase, Scopus, and the Cochrane Library through July 2025 for studies reporting EQ-5D outcomes. Twenty-four studies (281,958 participants, 15 countries) informed pooled mean EQ-5D utility and VAS estimates, while heterogeneity, publication bias, and multiple sensitivity and subgroup analyses were assessed. Results showed reduced HRQoL, with high between-study variability and inconsistent stage-specific findings.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/health-related-quality-of-life-in-patients-with-cervical-cancer-a-systematic-review-and-meta-analysis-of-eq-5d-utility-scores/350808/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/health-related-quality-of-life-in-patients-with-cervical-cancer-a-systematic-review-and-meta-analysis-of-eq-5d-utility-scores/350808.png","ImageObject",300,407,{"name":42,"@type":43},"pixelkiddo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of the systematic review and meta-analysis?","Question",{"text":63,"@type":64},"To pool EQ-5D utility and VAS outcomes for patients with cervical cancer and to support economic evaluations and health technology assessment using reference values for HRQoL.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which studies and EQ-5D outcome types were included?",{"text":68,"@type":64},"Eligible studies were adults with cervical cancer reporting EQ-5D-3L, EQ-5D-5L, EQ-5D VAS, or EQ-5D domain-level outcomes.",{"name":70,"@type":61,"acceptedAnswer":71},"How many studies and participants were included, and what did the pooled results show?",{"text":72,"@type":64},"Twenty-four studies with 281,958 participants from 15 countries were included. The pooled mean EQ-5D utility score was 0.79 and the pooled mean VAS score was 71.82, indicating reduced HRQoL.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350808,1790211489,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nHealth-related quality of life inpatients with cervical cancer:  \na systematic review and metaanalysis of EQ-5D utility scores  \nPriyankaaV1, Harshavardhan K1, Sananthya Karthikeyan2, Hariharan Murugadoss1 & Madhumitha Haridoss2,3􀀍  \nCervical cancer substantially impairs HRQoL, particularly among women in socially and economically productive age groups. EQ-5D utility values are important inputs for quality-adjusted life-year estimation, cost–utility analysis, and health technology assessment; however, pooled EQ-5D estimates for cervical cancer remain limited. This PRISMA 2020-compliant systematic review and meta-analysis searched PubMed, Embase, Scopus, and the Cochrane Library from inception to July  \n2025. The protocol was registered in PROSPERO (CRD420251077051) . Eligible studies included adults with cervical cancer reporting EQ-5D-3 L, EQ-5D-5 L, EQ-5D VAS, or EQ-5D domain-level outcomes. Random-effects meta-analysis was used to estimate pooled mean utility and VAS scores. Heterogeneity, publication bias, sensitivity analyses, subgroup analyses, prediction intervals, and meta-regression were assessed. Twenty-four studies including 281,958 participants from 15 countries were included. Seventeen studies contributed to the EQ-5D utility meta-analysis, yielding a pooled mean utility score of 0.79 (95% CI: 0.73–0.85; 95% prediction interval: 0.52–1.05; I² = 99.6%) . Seventeen studies reported EQ-5D VAS scores, with a pooled mean of 71.82 (95% CI: 67.95–75.69; 95% prediction interval: 54.54–89.11; I² = 98.3%). Stage-specific estimates were inconsistent, particularly for Stage IV disease, and should be interpreted cautiously because of small sample size, potential survivor bias, and high between-study variability. Pain/discomfort and anxiety/depression were the most frequently affected EQ-5D domains. Cervical cancer is associated with reduced HRQoL. The pooled EQ-5D estimates provide useful reference values for economic evaluations and HTA, but substantial heterogeneity and wide prediction intervals indicate that local adaptation and cautious interpretation are required.  \nKeywords EQ-5D, EUROQOL-5D, Health related quality of life, Cervical Cancer, Utility  \nAbbreviations  \nUHC  \nHPV  \nHTAQALYs VAS CENTRAL MeSH  \nDEF HRQoL ROB  \nAXIS  \nUniversal health coverage Human papilloma virus Health technology assessment Quality-adjusted life years Visual analogue scale  \nCochrane central register of controlled trials  \nMedical subject headings Data extraction form Health-related quality of life Risk of bias  \nAppraisal tool for cross-sectional studies  \n1Department of Pharmacy practice, Faculty of Medicine and Health Sciences, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, Tamilnadu, India. 2Division of Medical Research, SRM Medical College Hospital and Research Centre, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, Tamilnadu, India. 3Division of Medical Research, Research Centre, SRM Institute of science and technology, SRM Medical College Hospital, Kattankulathur 603203, Tamilnadu, India. 􀀍 email: [madhumih@srmist.edu.in](madhumih@srmist.edu.in)  \nRoB-2 Cochrane risk-of-bias tool  \nRCTs Randomized controlled trials  \nCIN Cervical intraepithelial neoplasia  \nEQ-5D EuroQol 5 dimension  \nHSUV Health state utility value WHO World health organization  \nCervical cancer is a malignant tumor of the cervix originating from the epithelial cells, usually in the form of squamous cell carcinoma or adenocarcinoma, associated with persistent infection by high-risk human papillomavirus types. Cervical cancer commonly develops in mid-adult life and often during the peak years of social and economic productivity. It has broad individual and societal implications1–3.  \nCervical cancer currently ranks as the fourth cause of cancer in women around the world, with an","cbCairwrYMqI08yX","https://ap.wps.com/l/cbCairwrYMqI08yX","pdf",2049380,11,"English","# Introduction\n## Background and global burden\n## Importance of HRQoL and EQ-5D\n# Methods\n## Eligibility criteria and data sources\n## Meta-analysis approach and assessments\n# Results\n## Included studies and pooled utility estimates\n## VAS estimates and domain impacts\n## Stage-specific findings and heterogeneity\n# Discussion\n## Implications for economic evaluations and HTA\n## Limitations and interpretation guidance","[{\"question\":\"What is the main objective of the systematic review and meta-analysis?\",\"answer\":\"To pool EQ-5D utility and VAS outcomes for patients with cervical cancer and to support economic evaluations and health technology assessment using reference values for HRQoL.\"},{\"question\":\"Which studies and EQ-5D outcome types were included?\",\"answer\":\"Eligible studies were adults with cervical cancer reporting EQ-5D-3L, EQ-5D-5L, EQ-5D VAS, or EQ-5D domain-level outcomes.\"},{\"question\":\"How many studies and participants were included, and what did the pooled results show?\",\"answer\":\"Twenty-four studies with 281,958 participants from 15 countries were included. The pooled mean EQ-5D utility score was 0.79 and the pooled mean VAS score was 71.82, indicating reduced HRQoL.\"}]","Health-related quality of life in patients with cervical cancer - a systematic review and meta-analysis of EQ-5D utility scores | PDF",1790091219,28,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f46253de087d32644f0b3a336ddbb7e1.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53ff3eda2c63e191cf9db2d1d4704f8c.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68c7f6ee4478151e35f89f451ec446d8.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe6095d7002624be91bc8f2cebe9813e.webp",980,1287]